Physician profile
Paul W Ford
NPI 1053315531
$2,061.67
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $443 · 2021: $904.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $446.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $374.40 | 2019-2021 | |
| Novo Nordisk INC | $361.54 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $202.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.78 | 2019-2021 | |
| Abbvie INC. | $132.45 | 2021 | |
| Sanofi-Aventis U.S. LLC | $86.03 | 2019-2021 | |
| Abbott Laboratories | $48.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $42.30 | 2021 | |
| Eisai INC. | $32.51 | 2020-2021 | |
| Amarin Pharma, INC. | $29.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.15 | 2019 | |
| Dexcom, INC. | $24.39 | 2021 | |
| Amgen INC. | $20.53 | 2019 | |
| Medtronic USA, INC. | $18.38 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.14 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.93 | 2019 | |
| Astellas Pharma US INC | $11.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.